Glaucoma - Pipeline Review, H2 2015 Now Available at iData Insights Glaucoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Glaucoma - Pipeline Review, H2 2015, provides an overview of the Glaucoma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Glaucoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand 1
business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179090/glaucoma-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179090/glaucoma-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 6 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Glaucoma Overview 11 Therapeutics Development 12 Pipeline Products for Glaucoma - Overview 12 Pipeline Products for Glaucoma - Comparative Analysis 13 Glaucoma - Therapeutics under Development by Companies 14 Glaucoma - Therapeutics under Investigation by Universities/Institutes 20 Glaucoma - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Glaucoma - Products under Development by Companies 25 Glaucoma - Products under Investigation by Universities/Institutes 32 Glaucoma - Companies Involved in Therapeutics Development 33 2
AC Immune SA 33 Acadia Pharmaceuticals Inc. 34 Advanced Refractive Technologies, Inc. 35 Aerie Pharmaceuticals, Inc. 36 Allergan Plc 37 Altacor Limited 38 Amakem NV 39 Asahi Kasei Pharma Corp. 40 AUS Bio Limited 41 Bausch & Lomb Incorporated 42 Bionure Farma, S.L. 43 Caladrius Biosciences, Inc. 44 Can-Fite BioPharma Ltd. 45 China Grand Wuhan General Pharmaceutical Research Institute 46 D. Western Therapeutics Institute, Inc. 47 DNAVEC Corporation 48 Dompe Farmaceutici S.p.A. 49 F. Hoffmann-La Roche Ltd. 50 Gene Signal International SA 51 Gilead Sciences, Inc. 52 Glaukos Corporation 53 GliaCure Inc. 54 Handok Inc. 55 3
Icon Bioscience, Inc. 56 IMMD Inc. 57 InMed Pharmaceuticals Inc. 58 Inotek Pharmaceuticals Corporation 59 InSite Vision Incorporated 60 Kadmon Corporation, LLC 61 Kala Pharmaceuticals, Inc. 62 Kukje Pharmaceutical Industry Co., Ltd. 63 Lacer, S.A. 64 Lee's Pharmaceutical Holdings Limited 65 Merck & Co., Inc. 66 Merz Pharma GmbH & Co. KgaA 67 Neurotech Pharmaceuticals, Inc. 68 NicOx S.A. 69 NoNO, Inc. 70 Ocata Therapeutics, Inc. 71 Ocular Therapeutix, Inc. 72 Oculis ehf 73 Ohr Pharmaceutical Inc. 74 Ono Pharmaceutical Co., Ltd. 75 Otsuka Holdings Co., Ltd. 76 Oxford BioMedica Plc 77 Quark Pharmaceuticals, Inc. 78 Quethera Limited 79 4
Regeneron Pharmaceuticals, Inc. 80 Sanofi 81 Santen Pharmaceutical Co., Ltd. 82 Senju Pharmaceutical Co., Ltd. 83 Shire Plc 84 SK Biopharmaceuticals Co., Ltd. 85 Sun Pharma Advanced Research Company Ltd. 86 Sylentis S.A. 87 ViSci Ltd. 88 vTv Therapeutics LLC 89 Glaucoma - Therapeutics Assessment 90 Assessment by Monotherapy Products 90 Assessment by Combination Products 91 Assessment by Target 92 Assessment by Mechanism of Action 97 Assessment by Route of Administration 101 Assessment by Molecule Type 103 Drug Profiles 105 (bimatoprost + brimonidine tartrate) - Drug Profile 105 (carteolol hydrochloride + latanoprost) - Drug Profile 106 (dorzolamide hydrochloride + latanoprost) - Drug Profile 107 (latanoprost + netarsudil mesylate) - Drug Profile 108 (latanoprost + trabodenoson) - Drug Profile 109 5
(tafluprost + timolol maleate) - Drug Profile 110 AC-262271 - Drug Profile 111 ACI-260 - Drug Profile 112 ACN-1052 - Drug Profile 113 aflibercept - Drug Profile 114 aganirsen - Drug Profile 117 ALT-022 - Drug Profile 119 ALY-1337 - Drug Profile 120 AMA-0076 - Drug Profile 121 Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 122 Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile 123 APH-1104 - Drug Profile 124 AR-13324 - Drug Profile 125 AR-13533 - Drug Profile 126 ATS-8535 - Drug Profile 127 BA-1049 - Drug Profile 128 BA-240 - Drug Profile 129 bamosiran - Drug Profile 130 bimatoprost - Drug Profile 132 bimatoprost - Drug Profile 133 bimatoprost SR - Drug Profile 134 BN-201 - Drug Profile 135 brimonidine tartrate - Drug Profile 136 6
CTI-085 - Drug Profile 137 DE-117 - Drug Profile 138 decorin - Drug Profile 139 Drug for Glaucoma - Drug Profile 140 Drug for Glaucoma - Drug Profile 141 Drugs for Steroid Induced Glaucoma - Drug Profile 142 Drugs to Inhibit Cadherin-5 for Glaucoma - Drug Profile 143 Drugs to Target Bestrophin-2 for Glaucoma - Drug Profile 144 GB-201 - Drug Profile 145 GB-202 - Drug Profile 146 GB-203 - Drug Profile 147 GB-204 - Drug Profile 148 GC-021109 - Drug Profile 149 Gene Therapy for Glaucoma - Drug Profile 150 Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 151 Gene Therapy for Ocular Diseases - Drug Profile 152 Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 153 Glaucoma-GT - Drug Profile 154 GS-607601 - Drug Profile 155 H-1129 - Drug Profile 156 HL-3501 - Drug Profile 157 HPP-851 - Drug Profile 158 IMD-1041 - Drug Profile 159 KJ-13003 - Drug Profile 160 7
KJ-14002 - Drug Profile 161 KL-00199 - Drug Profile 162 KR-12 - Drug Profile 163 LA-8045 - Drug Profile 164 latanoprost - Drug Profile 165 latanoprost - Drug Profile 166 latanoprost - Drug Profile 168 latanoprost - Drug Profile 169 latanoprost SR - Drug Profile 170 latanoprost SR - Drug Profile 172 latanoprostene bunod - Drug Profile 173 levobetaxolol hydrochloride - Drug Profile 175 lomerizine - Drug Profile 176 MD-920G - Drug Profile 177 MRZ-99030 - Drug Profile 178 NB-1111 - Drug Profile 179 NCX-1021 - Drug Profile 181 NCX-250 - Drug Profile 182 NCX-470 - Drug Profile 183 NCX-667 - Drug Profile 184 neurovitas - Drug Profile 185 NT-501 - Drug Profile 186 OC-201 - Drug Profile 189 8
OC-410 - Drug Profile 190 ONO-9054 - Drug Profile 191 OPA-6566 - Drug Profile 192 PBF-677 - Drug Profile 193 piclidenoson - Drug Profile 194 QPI-1007 - Drug Profile 196 R-801 - Drug Profile 198 R-807 - Drug Profile 200 Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 201 RO-5093151 - Drug Profile 203 SAR-366234 - Drug Profile 204 SHP-639 - Drug Profile 205 SKL-G - Drug Profile 206 Small Molecule for Glaucoma - Drug Profile 207 Read More http://www.idatainsights.com/reports-landing-page.php?id=179090/glaucoma-pipelinereview-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights
9
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
10